Dr Jennifer Nicholas

BSc MPhil PhD

Associate Professor
of Medical Statistics


Keppel Street
United Kingdom

+44 (0)20 7958 8119

I joined the LSHTM Department of Medical Statistics at the start of 2012, working on clinical trials and neurology research. Before this I was at King's College London Department of Primary Care and Public Health working in public health research and analyses of electronic health records. I have a PhD in Epidemiology from King's College London and MPhil in Epidemiology from University of Cambridge. Before starting my PhD I worked for two years as a public health epidemiologist in the NHS.


Faculty of Epidemiology and Population Health
Department of Medical Statistics


Centre for Statistical Methodology


I am lecturer and organiser for the Linear Regression course on MSc Medical Statistics, and module organiser and tutor for Basic Statistics for Clinical Trials on the MSc Clinical Trials (distance learning). I also co-organise and lecture on the Short Course Essentials of Clinical Trials.


My research interests are in randomised clinical trials and in non-randomised clinical studies. I have a methodological interest in clinical trial design in neurology, focusing on trials in dementia and multiple sclerosis. In particular, my research looks at the design of trials that incorporate medical imaging outcomes.

I have been involved in several multi-centre clinical trials. Currently my trials work focuses on researching new treatments for people with multiple sclerosis. I am working with the MS Society on the new OCTOPUS multi-arm multi-stage clinical trials to assess treatment for progressive multiple sclerosis. I am trial statistician for the MS-STAT2 randomised clinical trial, which is evaluating whether high dose simvastatin can slow progression of disability in secondary progressive multiple sclerosis. I have also worked with the LSHTM Clinical Trials Unit on trials which examine whether remote ischaemic conditioning can improve clinical outcomes.

I have an ongoing collaboration with the Dementia Research Centre, UCL, exploring genetic and other risk factors for the development of dementia and examining how dementia affects cognition, brain imaging and other biomarkers. As part of this work I am a co-investigator on GENFI, an international longitudinal study of familial frontotemporal dementia and working with UCL on the Insight 46 neuroscience sub-study of the MRC National Survey of Health and Development.

Research Area
Clinical trials
Public health
Statistical methods
Electronic health records
Randomised controlled trials
Disease and Health Conditions
Neurological disease
Kidney disease
United Kingdom
European Union

Selected Publications

Associations of β-Amyloid and Vascular Burden With Rates of Neurodegeneration in Cognitively Normal Members of the 1946 British Birth Cohort.
Keuss SE; Coath W; Nicholas JM; Poole T; Barnes J; Cash DM; Lane CA; Parker TD; Keshavan A; Buchanan SM
Designing Multi-arm Multistage Adaptive Trials for Neuroprotection in Progressive Multiple Sclerosis.
Li V; Leurent B; Barkhof F; Braisher M; Cafferty F; Ciccarelli O; Eshaghi A; Gray E; Nicholas JM; Parmar M
Olfactory testing does not predict β-amyloid, MRI measures of neurodegeneration or vascular pathology in the British 1946 birth cohort.
Buchanan SM; Parker TD; Lane CA; Keshavan A; Keuss SE; Lu K; James S-N; Murray-Smith H; Wong A; Nicholas J
Journal of neurology
Population-based blood screening for preclinical Alzheimer's disease in a British birth cohort at age 70.
Keshavan A; Pannee J; Karikari TK; Rodriguez JL; Ashton NJ; Nicholas JM; Cash DM; Coath W; Lane CA; Parker TD
Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction (CONDI-2/ERIC-PPCI): a single-blind randomised controlled trial.
Hausenloy DJ; Kharbanda RK; Møller UK; Ramlall M; Aarøe J; Butler R; Bulluck H; Clayton T; Dana A; Dodd M
Associations Between Vascular Risk Across Adulthood and Brain Pathology in Late Life: Evidence From a British Birth Cohort.
Lane CA; Barnes J; Nicholas JM; Sudre CH; Cash DM; Malone IB; Parker TD; Keshavan A; Buchanan SM; Keuss SE
JAMA neurology
Cognition at age 70: Life course predictors and associations with brain pathologies.
Lu K; Nicholas JM; Collins JD; James S-N; Parker TD; Lane CA; Keshavan A; Keuss SE; Buchanan SM; Murray-Smith H
Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study.
Moore KM; Nicholas J; Grossman M; McMillan CT; Irwin DJ; Massimo L; Van Deerlin VM; Warren JD; Fox NC; Rossor MN
The Lancet. Neurology
Accelerated long-term forgetting in presymptomatic autosomal dominant Alzheimer's disease: a cross-sectional study.
Weston PSJ; Nicholas JM; Henley SMD; Liang Y; Macpherson K; Donnachie E; Schott JM; Rossor MN; Crutch SJ; Butler CR
Lancet neurology
Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia
Rohrer JD; Woollacott IOC; Dick KM; Brotherhood E; Gordon E; Fellows A; Toombs J; Druyeh R; Cardoso MJ; Ourselin S
Presymptomatic cortical thinning in familial Alzheimer disease: A longitudinal MRI study.
Weston PSJ; Nicholas JM; Lehmann M; Ryan NS; Liang Y; Macpherson K; Modat M; Rossor MN; Schott JM; Ourselin S
Altered sense of humor in dementia.
Clark CN; Nicholas JM; Gordon E; Golden HL; Cohen MH; Woodward FJ; Macpherson K; Slattery CF; Mummery CJ; Schott JM
Journal of Alzheimer's disease
Remote Ischemic Preconditioning and Outcomes of Cardiac Surgery.
Hausenloy DJ; Candilio L; Evans R; Ariti C; Jenkins DP; Kolvekar S; Knight R; Kunst G; Laing C; Nicholas J
The New England journal of medicine
Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis.
Rohrer JD; Nicholas JM; Cash DM; van Swieten J; Dopper E; Jiskoot L; van Minkelen R; Rombouts SA; Cardoso MJ; Clegg S
Lancet neurology
Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial.
Chataway J; Schuerer N; Alsanousi A; Chan D; MacManus D; Hunter K; Anderson V; Bangham CRM; Clegg S; Nielsen C
See more Publications